ARQT — Arcutis Biotherapeutics, Inc. stock price, charts and financials
QT62Arcutis Biotherapeutics, Inc.Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
26.03
+0.09+0.35%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.03 | Insider Own | 18.07% | Shs Outstand | 125.08M | Perf Week | -8.41% |
| Market Cap | 3.26B | Forward P/E | 24.19 | EPS next Y | 1.08 | Insider Trans | -0.74% | Shs Float | 110.19M | Perf Month | -0.15% |
| Enterprise Value | 3.15B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 12.31% | Perf Quarter | 10.81% |
| Income | -3.00M | P/S | 7.83 | EPS this Y | 830.80% | Inst Trans | - | Short Ratio | 7.70 | Perf Half Y | 1.80% |
| Sales | 416.00M | P/B | 17.14 | EPS next Y | 390.85% | ROA | -0.52% | Short Interest | 13.56M | Perf YTD | -10.37% |
| Book/sh | 1.52 | P/C | 14.54 | EPS next 5Y | 90.85% | ROE | -1.41% | 52W High | 31.77 -18.07% | Perf Year | 82.16% |
| Cash/sh | 1.79 | P/FCF | 124.82 | EPS past 3/5Y | - | ROIC | 1.05% | 52W Low | 13.70 90.00% | Perf 3Y | 139.69% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 354.68% - | Gross Margin | 90.94% | Volatility | 3.69% 4.25% | Perf 5Y | 11.91% |
| Dividend TTM | - | EV/Sales | 7.56 | EPS Y/Y TTM | 97.41% | Oper. Margin | 0.77% | ATR (14) | 1.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.46 | Sales Y/Y TTM | 111.17% | Profit Margin | -0.57% | RSI (14) | 43.94 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.68 | EPS Q/Q | 55.00% | SMA20 | -5.73% | Beta | 1.47 | Target Price | 34.00 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | 59.09% | SMA50 | 1.87% | Rel Volume | 1.07 | Prev Close | 25.94 |
| Employees | 354 | LT Debt/Eq | 0.03 | Earnings | Aug 05 | SMA200 | 2.66% | Avg Volume | 1.82M | Price | 26.03 |
| IPO Date | Jan 31, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -39.91% 1.66% | Net Debt/EBITDA | 5.32 | Volume | 1,939,067 | Change | 0.35% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-26-26 | Reiterated | HC Wainwright & Co. | Buy | $30 → $34 |
| Nov-28-25 | Reiterated | Mizuho | Outperform | $32 → $37 |
| Oct-30-25 | Reiterated | Goldman Sachs | Neutral | $37 → $29 |
| Oct-29-25 | Reiterated | H.C. Wainwright | Buy | $22 → $30 |
| Oct-29-25 | Reiterated | Mizuho Securities | Outperform | $18 → $32 |
| Mar-11-25 | Reiterated | Jefferies | Buy | $19 |
| Dec-30-24 | Initiated | H.C | Buy | $19 |
| May-15-24 | Reiterated | Needham | Buy | $18 |
| May-15-24 | Reiterated | Mizuho | Buy | $8.00 → $18 |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy | $8.00 |
Latest News
Aug-03-26
Jul-29-26
Jul-29-2611:06AM
Jul-23-26
Jul-23-2611:00AM
Jul-21-26
Jul-21-2610:55AM
Jul-17-26
Jul-17-2610:10AM
Jul-16-26
Jul-15-26
Jul-15-2604:00PM
Jul-09-26
Jul-09-2601:37PM
Jul-08-26
Jul-08-2608:00AM
08:00AM
Jul-03-26
Jul-03-2608:37AM
Jul-02-26
Jul-02-2604:00PM
Jun-30-26
Jun-30-2609:15AM
Jun-29-26
Jun-29-2607:06PM
Company
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 416 | 376 | 197 | 60 | 4 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 38 | 37 | 19 | 5 | 1 | 1 | 0 | 0 | 0 | |
| Gross Profit | 379 | 339 | 177 | 55 | 3 | -1 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 284 | 275 | 229 | 185 | 122 | 61 | 21 | 6 | 2 | |
| Research and Development | 90 | 77 | 76 | 111 | 182 | 146 | 115 | 37 | 18 | |
| Other Operating Expense | 1 | 0 | 1 | 0 | 1 | -1 | 0 | 0 | 0 | |
| Operating Income | 3 | -12 | -128 | -241 | -302 | -207 | -137 | -43 | -20 | |
| Interest Expense | 13 | 12 | 27 | 30 | 16 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 9 | 16 | 12 | 6 | 0 | 1 | 1 | 0 | |
| Net Income Before Taxes | -2 | -15 | -139 | -259 | -311 | -206 | -136 | -42 | -19 | |
| Income Taxes | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -3 | -16 | -140 | -262 | -311 | -206 | -136 | -42 | -19 | |
| Net Income From Continuing Operations | -3 | -16 | -140 | -262 | -311 | -206 | -136 | -42 | -19 | |
| Net Income | -3 | -16 | -140 | -262 | -311 | -206 | -136 | -42 | -19 | |
| EPS (Recurring) | -0.02 | -0.13 | -1.16 | -3.78 | -5.66 | -4.17 | -3.80 | -1.10 | -0.53 | |
| EPS (Basic, Before Extraordinaries) | -0.02 | -0.13 | -1.16 | -3.78 | -5.66 | -4.17 | -3.80 | -1.10 | -0.53 | |
| EPS (Diluted) | -0.03 | -0.13 | -1.16 | -3.78 | -5.66 | -4.17 | -3.80 | -1.10 | -0.53 | |
| EBITDA | 15 | 2 | -110 | -227 | -295 | -206 | -135 | -42 | 0 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 8.07 | 9.81 | 8.56 | 3.71 | 203.50 | — | — | — | — | |
| Gross Margin | 91.11 | 90.16 | 89.85 | 91.67 | 75.00 | — | — | — | — | |
| Operating Margin | 0.72 | -3.19 | -64.97 | -401.67 | -7,550.00 | — | — | — | — | |
| Net Margin | -0.72 | -4.26 | -71.07 | -436.67 | -7,775.00 | — | — | — | — | |
| Shares Outstanding | 129 | 127 | 121 | 69 | 55 | 49 | 36 | 38 | 36 | |
| Market Capitalization | 3,358 | 3,688 | 1,686 | 223 | 814 | 1,016 | 1,013 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Welgus Howard G. | Director | Jul 15 '26 | Option Exercise | 7.93 | 4,096 | 32,475 | 41,839 | Jul 17 |
| Welgus Howard G. | Director | Jul 15 '26 | Sale | 26.91 | 4,730 | 127,284 | 37,109 | Jul 17 |
| Welgus Howard G. | Director | Jun 17 '26 | Sale | 25.67 | 635 | 16,300 | 37,743 | Jun 17 |
| Welgus Howard G. | Director | Jun 15 '26 | Sale | 24.41 | 4,096 | 99,980 | 38,378 | Jun 17 |
| LIN SUE-JEAN | Director | Jun 15 '26 | Sale | 24.38 | 4,946 | 120,587 | 27,567 | Jun 17 |
| Welgus Howard G. | Director | Jun 15 '26 | Option Exercise | 7.93 | 4,096 | 32,475 | 42,474 | Jun 17 |
| Vairavan Latha | SVP Chief Financial Officer | May 11 '26 | Sale | 21.05 | 435 | 9,157 | 85,978 | May 13 |
| Burnett Patrick | See Remarks | May 11 '26 | Sale | 21.05 | 222 | 4,673 | 120,244 | May 13 |
| Matsuda Masaru | See Remarks | May 04 '26 | Sale | 23.31 | 8,256 | 192,415 | 126,689 | May 06 |
| Burnett Patrick | See Remarks | May 04 '26 | Sale | 23.61 | 684 | 16,150 | 120,466 | May 06 |
| Vairavan Latha | SVP Chief Financial Officer | May 04 '26 | Sale | 23.61 | 1,341 | 31,662 | 86,413 | May 06 |
| Watanabe Todd | See Remarks | May 04 '26 | Sale | 23.61 | 3,172 | 74,893 | 720,755 | May 06 |
| Welgus Howard G. | Director | May 01 '26 | Sale | 22.99 | 7,144 | 164,220 | 32,600 | May 05 |
| Welgus Howard G. | Director | Apr 01 '26 | Sale | 23.88 | 10,000 | 238,801 | 39,744 | Apr 03 |
| Leonard Keith R | Director | Mar 02 '26 | Option Exercise | 8.28 | 39,272 | 325,231 | 61,395 | Mar 04 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.